News
ASCO 2025, prostate cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), enzalutamide, 8-Year Outcomes of Enzalutamide Versus a Non-Steroidal Anti-Androgen, ENZAMET trial, ANZUP 1304 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback